BSE filing, NSE: SHK. Summary written from the filing by ALFA Finder's alert engine.
S H Kelkar & Company Ltd: key numbers
- Share price
- ₹131.20
- Market cap
- ₹1,816 Cr
- Revenue (annual)
- ₹2,368 Cr
- Net profit (annual)
- ₹69.26 Cr
- P/E (TTM)
- 20.4×Sector 38.6×
- Promoter holding
- 54.87%+0.00% QoQ
- FII holding
- 5.27%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from S H Kelkar & Company Ltd
All →S H Kelkar & Company Legal & Regulatory
S H Kelkar received cautionary letters from BSE and NSE for filing late the schedule of an analyst meet held on March 3, 2025. The company states the matter had no financial impact.
S H Kelkar & Company Share Pledge
Promoter group entity Keva Constructions released a pledge on 15.99 lakh equity shares. The company reports no shares are currently under pledge.
- Value
- ₹21.59 Cr
S H Kelkar & Company Share Pledge
Keva Constructions Private Limited, a promoter group entity, released a pledge on 47.01 lakh equity shares. The transaction value of the released pledge is Rs. 65.01 Crore.
- Value
- ₹65.01 Cr
S H Kelkar & Company Board Meeting Date
S H Kelkar & Co. announced its board meeting on November 02, 2026, to consider unaudited Q1 and H1 FY27 results. No financial figures are disclosed in this advance notice.
S H Kelkar & Company Business Update
S H Kelkar reported Q2 FY 2026-27 consolidated revenues of Rs. 632.7 crore, marking 15% growth. Net debt stood at Rs. 911 crore as of September 30.
S H Kelkar & Company Management Change
S H Kelkar and Company Limited announced the resignation of EVP Vivek Kulkarni. Rajeev Mishra was appointed Vice President – Sales & Ingredients Division, effective October 01, 2026.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.